Cargando…
Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States
Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum(®) COVID-19 Electronic H...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421058/ https://www.ncbi.nlm.nih.gov/pubmed/35996822 http://dx.doi.org/10.1177/10760296221120421 |
_version_ | 1784777510735577088 |
---|---|
author | Peacock, W. Frank Crawford, James M. Chen, Yen-Wen (Cindy) Ashton, Veronica Campbell, Alicia K. Milentijevic, Dejan Spyropoulos, Alex C. |
author_facet | Peacock, W. Frank Crawford, James M. Chen, Yen-Wen (Cindy) Ashton, Veronica Campbell, Alicia K. Milentijevic, Dejan Spyropoulos, Alex C. |
author_sort | Peacock, W. Frank |
collection | PubMed |
description | Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum(®) COVID-19 Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, and anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients with COVID-19 diagnosis, 141 471 met entry criteria. Mean (standard deviation [SD]) age was 46.1 (17.2) years, 56.8% were female, 72.9% Caucasian, 11.2% African American, and 11.1% Hispanic. Comorbidity burden was low (mean [SD] Quan-Charlson comorbidity index score of 0.43 [1.10]); however, of those with body mass index data, half were obese. During the follow-up period, a TEE occurred in 1.4%, with the proportion of patients with ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism being similar (approximately 0.4% each). All-cause mortality was 0.7%. Medications included corticosteroids (13.7%), anticoagulants (4.9%), and antiplatelets (2.9%). Overall, in this large cohort analysis, certain demographic and clinical characteristics of patients who experienced TEEs were identified and may help guide management decisions and future clinical trials for COVID-19 outpatients. |
format | Online Article Text |
id | pubmed-9421058 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-94210582022-08-30 Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States Peacock, W. Frank Crawford, James M. Chen, Yen-Wen (Cindy) Ashton, Veronica Campbell, Alicia K. Milentijevic, Dejan Spyropoulos, Alex C. Clin Appl Thromb Hemost Original Manuscript Limited data are available on thromboembolic events (TEEs) and mortality in outpatients with coronavirus disease 2019 (COVID-19). This retrospective, observational cohort study identified non-hospitalized COVID-19 outpatients (01/21/2020-01/07/2021) using de-identified Optum(®) COVID-19 Electronic Health Records data. Patient characteristics, occurrence of TEEs, all-cause mortality, and anticoagulant or thrombolytic medication use were evaluated. Of 1,246,067 patients with COVID-19 diagnosis, 141 471 met entry criteria. Mean (standard deviation [SD]) age was 46.1 (17.2) years, 56.8% were female, 72.9% Caucasian, 11.2% African American, and 11.1% Hispanic. Comorbidity burden was low (mean [SD] Quan-Charlson comorbidity index score of 0.43 [1.10]); however, of those with body mass index data, half were obese. During the follow-up period, a TEE occurred in 1.4%, with the proportion of patients with ischemic stroke, myocardial infarction, deep vein thrombosis, and pulmonary embolism being similar (approximately 0.4% each). All-cause mortality was 0.7%. Medications included corticosteroids (13.7%), anticoagulants (4.9%), and antiplatelets (2.9%). Overall, in this large cohort analysis, certain demographic and clinical characteristics of patients who experienced TEEs were identified and may help guide management decisions and future clinical trials for COVID-19 outpatients. SAGE Publications 2022-08-22 /pmc/articles/PMC9421058/ /pubmed/35996822 http://dx.doi.org/10.1177/10760296221120421 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Original Manuscript Peacock, W. Frank Crawford, James M. Chen, Yen-Wen (Cindy) Ashton, Veronica Campbell, Alicia K. Milentijevic, Dejan Spyropoulos, Alex C. Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States |
title | Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States |
title_full | Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States |
title_fullStr | Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States |
title_full_unstemmed | Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States |
title_short | Real-World Analysis of Thromboembolic Events and Mortality of COVID-19 Outpatients in the United States |
title_sort | real-world analysis of thromboembolic events and mortality of covid-19 outpatients in the united states |
topic | Original Manuscript |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9421058/ https://www.ncbi.nlm.nih.gov/pubmed/35996822 http://dx.doi.org/10.1177/10760296221120421 |
work_keys_str_mv | AT peacockwfrank realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates AT crawfordjamesm realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates AT chenyenwencindy realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates AT ashtonveronica realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates AT campbellaliciak realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates AT milentijevicdejan realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates AT spyropoulosalexc realworldanalysisofthromboemboliceventsandmortalityofcovid19outpatientsintheunitedstates |